首页|布地奈德及特布他林联合噻托溴铵治疗老年慢阻肺的临床效果

布地奈德及特布他林联合噻托溴铵治疗老年慢阻肺的临床效果

扫码查看
目的 探讨布地奈德及特布他林联合噻托溴铵治疗老年慢性阻塞性肺疾病(慢阻肺,COPD)的临床效果。方法 94 例老年COPD患者,随机分为对照组和观察组,每组 47 例。对照组使用布地奈德及特布他林治疗,观察组在对照组基础上使用噻托溴铵治疗。比较两组临床疗效,肺功能指标,炎性因子,血气分析指标及慢阻肺评估测试问卷(CAT)评分。结果 观察组治疗总有效率 95。74%高于对照组的 74。47%(P<0。05)。观察组治疗后第 1 秒用力呼气容积(FEV1)、用力肺活量(FVC)、呼气峰流速(PEF)、每分钟最大通气量(MVV)分别为(2。46±0。45)L、(2。98±0。40)L、(3。79±0。53)L/s、(62。38±10。34)L,均高于对照组的(1。81±0。42)L、(2。71±0。37)L、(3。03±0。51)L/s、(58。13±9。19)L(P<0。05)。观察组治疗后降钙素原(PCT)(0。36±0。10)μg/L、C反应蛋白(CRP)(5。21±2。08)mg/L、肿瘤坏死因子-α(TNF-α)(6。18±2。09)ng/L、白细胞介素-6(IL-6)(6。72±1。13)ng/L均低于对照组的(0。75±0。13)μg/L、(10。47±2。76)mg/L、(10。34±2。82)ng/L、(10。94±1。65)ng/L(P<0。05)。观察组治疗后动脉血氧分压(PaO2)(80。67±6。15)mm Hg(1 mm Hg=0。133 kPa)高于对照组的(71。43±5。78)mm Hg,动脉血二氧化碳分压(PaCO2)(42。28±3。59)mm Hg、CAT评分(15。12±4。06)分低于对照组的(54。81±4。12)mm Hg、(20。66±5。23)分(P<0。05)。结论 布地奈德及特布他林联合噻托溴铵治疗老年COPD的临床效果显著,能有效抑制炎症反应,扩张支气管,改善肺功能,促进血气指标恢复,缓解病情。
Clinical effect of budesonide and terbutaline combined with tiotropium bromide in the treatment of chronic obstructive pulmonary disease in the elderly
Objective To explore the clinical effect of budesonide and terbutaline combined with tiotropium bromide in the treatment of chronic obstructive pulmonary disease(COPD)in the elderly.Methods 94 elderly patients with COPD were randomly divided into a control group and an observation group,with 47 cases in each group.The control group was treated with budesonide and terbutaline,and the observation group was treated with tiotropium bromide based on the control group.The clinical efficacy,lung function indicators,inflammatory factors,blood gas analysis indicators and COPD assessment test(CAT)score were compared between the two groups.Results The total effective rate of the observation group was 95.74%,which was higher than 74.47%of the control group(P<0.05).After treatment,the forced expiratory volume in one second(FEV1),forced vital capacity(FVC),peak expiratory flow rate(PEF)and maximum voluntary volume(MVV)in the observation group were(2.46±0.45)L,(2.98±0.40)L,(3.79±0.53)L/s and(62.38±10.34)L,which were higher than(1.81±0.42)L,(2.71±0.37)L,(3.03±0.51)L/s and(58.13±9.19)L in the control group(P<0.05).After treatment,the procalcitonin(PCT),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)were(0.36±0.10)μg/L,(5.21±2.08)mg/L,(6.18±2.09)ng/L and(6.72±1.13)ng/L,which were all lower than(0.75±0.13)μg/L,(10.47±2.76)mg/L,(10.34±2.82)ng/L and(10.94±1.65)ng/L in the control group(P<0.05).After treatment,the arterial partial pressure of oxygen(PaO2)of the observation group was(80.67±6.15)mm Hg(1 mm Hg=0.133 kPa),which was higher than(71.43±5.78)mm Hg of the control group;the arterial partial pressure of carbon dioxide(PaCO2)and CAT score were(42.28±3.59)mm Hg and(15.12±4.06)points in observation group,which were lower than(54.81±4.12)mm Hg and(20.66±5.23)points in the control group(P<0.05).Conclusion Budesonide and terbutaline combined with tiotropium bromide has significant clinical effect in treating COPD in the elderly,which can effectively inhibit inflammatory reaction,dilate bronchi,improve lung function,promote the recovery of blood gas indexes and relieve the condition.

Chronic obstructive pulmonary diseaseBudesonideTerbutalineTiotropium bromideOld age

周晓明

展开 >

362100 福建省惠安县总医院呼吸与危重症医学科

慢性阻塞性肺疾病 布地奈德 特布他林 噻托溴铵 老年

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(7)
  • 14